Compare Manulife Financial Corporation (MFC) vs Revvity Inc (RVTY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Manulife Financial Corporation vs Revvity Inc — how do they compare? Manulife Financial Corporation trades at $44.02 (market cap $72.68B), while Revvity Inc trades at $115.28 (market cap $12.91B). The key difference: Manulife Financial Corporation is far larger — about 5.6× Revvity Inc's market cap, and Manulife Financial Corporation pays the higher dividend (3.1%). Which is the better fit depends on your goals.
| MFC | RVTY | |
|---|---|---|
Market Cap | $72.68B | $12.91B |
Sector | Financials | Technology |
52-Week High | $44.77 | $117.75 |
52-Week Low | $30.06 | $82.26 |
Enterprise Value | $67.84B | $15.23B |
Dividend Yield | 3.1% | 0.24% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Manulife Financial (MFC) trades at $44.15, down 0.38% on the day, with a bullish technical signal from moving averages and neutral oscillators. Revenue grew to $53.01B in 2025, with net income of $5.78B, and the company has a strong analyst consensus of 57% buy ratings. Recent Q2 2026 earnings beat expectations, driven by Asia growth and insurance sales, while dividends of $0.49 per share were declared for H1 and H2 2026.
MFC's outlook is positive due to earnings momentum and strategic AI partnerships, but risks include premium valuation and segment volatility. The stock offers steady dividends and growth potential, though investors should monitor execution in wealth management and macroeconomic impacts on insurance demand.
RVTY trades at $115.18, down 0.72% on the day, with a bullish technical signal from moving averages and neutral oscillators. The company reported strong Q2 2026 earnings of $1.41 per share, beating estimates, and raised its full-year outlook, driven by diagnostics strength and AI-enabled drug discovery. Revenue for 2025 was $2.86 billion with a net income margin of 8.16%, though valuation ratios like P/E of 55.64 appear elevated. Recent news includes product launches like the SuperFlex prenatal system and presentations at investor conferences.
The outlook is positive with analyst consensus favoring a buy rating and a $120.50 price target, suggesting upside. Key opportunities include robust diagnostics demand and innovation pipelines, while risks involve high valuation multiples and competitive pressures in the healthcare sector. Cash flow improved in 2026 to a net positive $31 million, supporting growth initiatives.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Manulife Financial Corporation
Manulife provides life insurance and wealth management products and services to individuals and group customers in Canada, the United States, and Asia. Manulife is one of Canada's Big Three Life Insurance companies (the other two are Sun Life and Great West Life). As of Dec. 31, 2021, Manulife reported assets under management or administration of about CAD $1.4 trillion.
Read more on MFC →About Revvity Inc
Revvity, Inc., formerly the Life Sciences and Diagnostics businesses of PerkinElmer, is a global provider of scientific and diagnostic solutions. The company focuses on the health and wellness of humanity through its expertise in life science research, detection, imaging, and informatics. Revvity supplies a broad portfolio of instruments, reagents, and services to pharmaceutical companies, academic research institutions, and clinical laboratories worldwide, enabling customers to make advancements in human health.
Read more on RVTY →
